Search
Bicifadine
go.drugbank.com/drugs/DB04889InvestigationalBicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesBecocalcidiol
go.drugbank.com/drugs/DB04891InvestigationalBecocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.
Categories: Vitamin D and AnaloguesAZD3409
go.drugbank.com/drugs/DB04893ExperimentalAZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.
Categories: Heterocyclic Compounds, 1-RingMilnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigational(BACE-1), which has investigationally been associated with β-amyloid plaque formation - making the agent a possible course of treatment for Alzheimer's disease [A175957]. … Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsThymalfasin
go.drugbank.com/drugs/DB04900InvestigationalThymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide. … Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. It is also used to boost the immune response in the treatment of other diseases.
Synonyms: Thymosin α-1, Thymosin alpha 1Pagoclone
go.drugbank.com/drugs/DB04903InvestigationalIt is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures
Categories: Heterocyclic Compounds, 2-RingOritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigational[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 InhibitorsStannsoporfin
go.drugbank.com/drugs/DB04912InvestigationalStannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds with 4 or More RingsAlfimeprase
go.drugbank.com/drugs/DB04919InvestigationalAlfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (<i>Agkistrodon contortrix contortrix</i>). … It is a small protein that contains 203 residues (Randolph et al. 1992). Alfimeprase is being developed by Nuvelo.
Synonyms: 3-203-FIBROLASE (3-SERINE) (AGKISTRODON CONTORTRIX CONTORTRIX RECOMBINANT)Neramexane
go.drugbank.com/drugs/DB04926InvestigationalNeramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.